Rezlidhia

Obtain blood counts and blood chemistries including liver function tests prior to initiation, at least once weekly for the first 2 months, once every other week for the 3^rd month, once in the 4^th month, and once every other month thereafter. Withhold treatment if differentiation syndrome is suspected, and initiate systemic corticosteroids (eg, dexamethasone 10mg IV every 12hrs for at least 3 days) and hemodynamic monitoring until symptom resolution; initiate hydroxyurea if concomitant leukocytosis is observed. Withhold, reduce, or permanently discontinue if hepatic dysfunction occurs; monitor frequently for clinical symptoms (eg, fatigue, anorexia, right upper abdominal discomfort, dark urine, jaundice). Mild (total bilirubin ULN and any AST >ULN or total bilirubin >1–1.5xULN and any AST) or moderate (total bilirubin >1.5–3xULN and any AST) hepatic impairment: increased risk of differentiation syndrome; monitor closely. Severe renal impairment (CrCL 15–29mL/min), renal failure (CrCL <15mL/min), on dialysis, or severe hepatic impairment (total bilirubin >3xULN with any AST): dosage not established. Pregnancy. Nursing mothers: not recommended (during and for 2 weeks after the last dose).